Answers are grounded in this paper and cite their sources.
Mini Review Basics o f Granulocyte transfusionsMobilization is achieved using single-or double-dose corticosteroids (Dexamethasone 8-12 mg or prednisolone) with or without granulocyte colony-stimulating factor (G-CSF, 5-10 μg/kg subcutaneously).A commonly used fixed-dose regimen includes dexamethasone 8 mg and G-CSF 450 μg given 12 hours prior to apheresis.[9][10][11] A study conducted on 20 donors showed that G-CSF alone yields more granulocytes than dexamethasone alone (41.1 ± 20.4 × 10⁹ vs 21.0 ± 10.0 × 10⁹; p < 0.001), but the combination of G-CSF and dexamethasone results in the highest yield (67.1 ± 22.0 × 10⁹; p < 0.002).12 In a 5-week crossover study done on five participants who received various single-dose regimens of G-CSF and dexamethasone, peak absolute neutrophil count (ANC) was observed at 12 hours across all regimens.The combination introduction Bacterial and fungal infections are one of the major causes of mortality and morbidity in recipients of hematopoietic stem cell transplants (HSCT) with treatment-related neutropenia.Multidrugresistant organisms (MDROs) are increasingly responsible for infections in HSCT recipients.One of the institutional studies from India showed the prevalence of MDRO (carbapenem-resistant Enterobacteriaceae) as high as 60% in pediatric oncology patients, causing significant mortality.1 With increasing resistance to antimicrobial agents, the use of granulocyte transfusions (GTX) is being increasingly utilized for the early clearance of infections in these neutropenic patients.2,3 Apart from the antimicrobial effect of GTX, there is growing interest in assessing the immunomodulatory effect and potential antitumor effects.4,5 The standard volume of granulocyte apheresis products ranges around 300 mL with a hematocrit of 15-40% depending on the blood volume processed, use of a sedimenting agent (e.g., Hydroxyethyl starch-HES), and type of cell separator used.6,7 In the presence of red blood cells (RBCs), white blood cells (WBCs), and platelets with a significant amount of plasma, a granulocyte product usually acts similarly to "whole blood."As per the Association for the Advancement of Blood and Biotherapies (AABB) recommendations, granulocyte products should be of the same ABO type and cross-match compatible with the patient.8 Provision of a similar ABO type of granulocyte product becomes a challenge when supporting patients undergoing ABO-mismatched HSCT.We aim to present a short report on the possible influence of using ABO-mismatch granulocyte transfusion in HSCT settings and measures that can be taken to reduce the risk.
No takes yet. Share an insight, caveat, or question.
Arora et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: